论文部分内容阅读
目的探讨人类血清激肽释放酶10(humankallikrein10,hk10)在卵巢癌诊断和预后判断中的价值。方法ELISA法检测卵巢癌组、妇科良性疾病组、正常对照组的血清hk10浓度/阳性率并与CA125进行比较,动态观察卵巢癌患者术后第1、5、10天hk10的浓度。结果hk10诊断卵巢癌的灵敏度为59%,特异性为89%;卵巢癌组hk10浓度/阳性率(浓度为603～1742ng/L,平均浓度为1093ng/L/59%)明显高于妇科良性疾病组(浓度为52～1142ng/L,平均为516ng/L/3%)和正常健康女性对照组(浓度为73～925ng/L,平均为460ng/L/0);卵巢癌患者血清hk10浓度于术后第10天降至正常;联合应用hk10和CA125诊断卵巢癌的阳性率明显升高,hk10的浓度与卵巢癌的分级、分期、组织分化程度有关。结论血清hk10是卵巢癌诊断和预后判断的有价值的指标,联合应用hk10和CA125可使卵巢癌,尤其是早期卵巢癌的阳性率提高。
Objective To investigate the value of human serum kallikrein 10 (hk10) in the diagnosis and prognosis of ovarian cancer. Methods The serum hk10 concentration / positive rate in ovarian cancer group, benign gynecological disease group and normal control group were detected by ELISA. The concentration of hk10 in ovarian cancer patients was detected on the 1st, 5th and 10th day after operation compared with CA125. Results The sensitivity and specificity of hk10 in the diagnosis of ovarian cancer were 59% and 89% respectively. The hk10 concentration / positive rate in ovarian cancer group (concentration of 603 ~ 1742ng / L, average 1093ng / L / 59%) was significantly higher than that of benign gynecological diseases The serum hk10 level in ovarian cancer patients was higher than that in normal healthy women (concentration ranged from 73 ng / L to 925 ng / L, averaged 460 ng / L / 10 days after the operation to normal; combined application of hk10 and CA125 positive rate of ovarian cancer was significantly increased, hk10 concentration and ovarian cancer grade, stage, degree of tissue differentiation. Conclusions Serum hk10 is a valuable index for the diagnosis and prognosis of ovarian cancer. The combination of hk10 and CA125 can increase the positive rate of ovarian cancer, especially early stage ovarian cancer.